Jonathan Roses was the lead author on behalf of the Boston Patent Law Association’s (BPLA’s) Patent Office Practice and Licensing Committees of an April 2021 Response to a Notice of Proposed Rulemakin...
Discretionary denial has been a hot topic at the PTAB. On Wednesday, February 24th, Wolf Greenfield hosted a webinar to discuss discretionary denial at the PTAB, and in particular, discretionary denia...
Jonathan Roses was the lead author on behalf of the Boston Patent Law Association's (BPLA’s) Patent Office Practice and ad hoc Diversity & Inclusion Committees of a February 2021 Response to USPTO...
Overview On December 11, 2020, the PTAB issued a Final Written Decision in Illumina, Inc. v. Natera, Inc., IPR2019-01201, upholding the validity of Natera Inc.’s patent for determining genetic data fr...
An article written by Rob Sahr titled “Protecting Pharmaceutical Exclusivity: Avoiding the Hidden Dangers of Double Patenting” was published in Pharmaceutical Commerce. Read more.
Overview On August 3, 2020, the United States Court of Appeals for the Federal Circuit partially reversed a District Court’s decision for a permanent injunction against 10X Genomics. Bio-Rad Laborator...
An article written by Jonathan Roses and Alexander Lee, associate at Hoffmann Eitle, titled "Doctrine of Equivalents in US and European Patent Law" was published in The Pharma Letter. Read more (subsc...
An article written by Jonathan Roses and Matthew Birkett, partner at Hoffmann Eitle, titled "Salt and Solid Form Issues in US and European Patents" was published in The Pharma Letter. Read more (subsc...
An article written by Mike Pomianek and Jason Balich titled “Manufacturing Abroad to Avoid Infringing a Method Patent” was published in the fall 2020 edition of Today’s General Counsel. Read more.
An article written by Jonathan Roses and Matthew Birkett, partner at Hoffmann Eitle, titled "Double Patenting in the USA and Europe" was published in The Pharma Letter. Read more (subscription require...
An article written by Jonathan Roses and Toby Simpson, partner at Hoffmann Eitle, titled “The intersection of regulatory and patent exclusivities for the life sciences industry: a comparative overview...
A stay is an important mechanism for many defendants to consider when filing an IPR. Due to the ongoing pandemic, courts have had to shift resources to address COVID-19-related concerns. In some insta...